Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia-inducible factor 1 (HIF-1) is a nuclear protein involved in mammalian oxygen homeostasis.
Hypoxia inducible factor-1 (HIF-1) is a major transcription factor that is composed of two subunits: HIF-1 alpha and HIF-1 beta, the latter being a constitutively-expressed aryl hydrocarbon receptor nuclear transporter (ARNT).
Prolyl hydroxylase domain (PHD) proteins, including PHD1, PHD2, and PHD3, mediate oxygen-dependent degradation of hypoxia-inducible factor (HIF) alpha subunits. Suppression of PHD enzymes leads to stabilization of HIFs and offers a potential treatment option for many ischemic disorders, such as peripheral artery occlusive disease, myocardial infarction, and stroke (1).
The HIF family are heterodimeric, oxygen-sensitive transcription factors comprising an alpha and beta subunit which are normally dissociated in normoxic conditions. Our antibody catalog contains products targeting all the Hypoxia Inducible Factor isoforms which have been identified in mammalian cells. These include HIF-2 alpha antibody reagents targeting both the entire protein and specific epitopes.
The hypoxia inducible factors are a family of heterodimeric transcription factors which are activated in response to lowered oxygen levels, or hypoxia. Although it may seem that HIF-1 alpha receives all the attention, other HIF antibodies, such as the HIF-2 alpha and HIF-1 beta antibody, are frequently used in clinical research as well.
Hypoxia-Inducible Factor-1 (HIF-1) is a highly conserved heterodimeric transcription factor. Novus' antibody catalogue contains an extensive range of both HIF-1 alpha and HIF-1 beta, useful for hypoxia, angiogenesis, cancer and many other areas of research.